Research is exploring the mechanisms of resistance to immune checkpoint blockade in melanoma, with studies suggesting that metabolic reprogramming and other factors may contribute to immune escape. The use of various techniques, including transcriptomics and proteomics, is helping to map the molecular and functional landscape of this resistance. Findings from related studies on other types of cancer, such as brain metastases and colorectal cancer, may also have implications for understanding and targeting immune resistance in melanoma.